Cost-Effectiveness of Fidaxomicin for Clostridium difficile Treatment
نویسندگان
چکیده
منابع مشابه
Cost-effectiveness of fidaxomicin for Clostridium difficile treatment.
TO THE EDITOR—Bartsch and colleagues recently evaluated the cost-effectiveness of fidaxomicin treatment for Clostridium difficile infection and should be commended for addressing this important question [1]. In light of a recent Centers for Disease Control and Prevention report estimating 250 000 C. difficile infections per year resulting in 14 000 deaths and excess medical costs of $1 billion ...
متن کاملFidaxomicin for Clostridium difficile Infection.
To the Editor: In their randomized study comparing fidaxomicin with vancomycin for Clostridium difficile infection, Louie et al. (Feb. 3 issue)1 found that substantially fewer patients in the fidaxomicin group had recurrences of C. difficile infection within 4 weeks after the conclusion of treatment. We recently reported on an observational study involving U.S. veterans in which the recurrence ...
متن کاملCost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection
OBJECTIVES Fidaxomicin was non-inferior to vancomycin with respect to clinical cure rates in the treatment of Clostridium difficile infections (CDIs) in two Phase III trials, but was associated with significantly fewer recurrences than vancomycin. This economic analysis investigated the cost-effectiveness of fidaxomicin compared with vancomycin in patients with severe CDI and in patients with t...
متن کاملFidaxomicin for Clostridium difficile-Associated Diarrhoea
BACKGROUND Fidaxomicin is a macrocyclic antibiotic approved in 2011 by the US Food and Drug Administration for treatment of Clostridium difficile-associated diarrhoea (CDAD). OBJECTIVE Herein, we present an epidemiological method to estimate, on a case mix basis, and from the perspective of the US health system, the warranted (justifiable) price per day for fidaxomicin, as a percent of the wh...
متن کاملFidaxomicin (Dificid) for Clostridium difficile infection.
Volume 87, Number 3 www.aafp.org/afp American Family Physician 211 Fidaxomicin (Dificid) is an oral macrolide antibiotic labeled for the treatment of Clostridium difficile–associated diarrhea in adults. It primarily exhibits activity against species of clostridia, mainly C. difficile, while having no or limited activity against normal gastrointestinal flora. It joins the standard treatments of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Infectious Diseases
سال: 2013
ISSN: 1058-4838,1537-6591
DOI: 10.1093/cid/cit772